Detalhe da pesquisa
1.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol
; 184: 168-177, 2024 Feb 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38325276
2.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38129136
3.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37052965
4.
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Cancer
; 129(12): 1846-1855, 2023 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37060236
5.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36965291
6.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Br J Cancer
; 127(8): 1479-1486, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35869143
7.
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Gynecol Oncol
; 167(3): 436-443, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36220670
8.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 267-276, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33539744
9.
Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
Curr Oncol Rep
; 23(12): 147, 2021 11 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34748099
10.
Oligometastatic prostate cancer treatment.
Future Oncol
; 17(29): 3893-3899, 2021 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-34296622
11.
Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.
Int J Gynecol Cancer
; 31(1): 110-113, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32796087
12.
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Int J Gynecol Cancer
; 31(6): 875-882, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33931498
13.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
; 31(10): 1348-1355, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34462317
14.
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Int J Cancer
; 146(2): 439-448, 2020 01 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31381147
15.
Treatment of recurrent epithelial ovarian cancer.
Cancer
; 125 Suppl 24: 4609-4615, 2019 Dec 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31967680
16.
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Gynecol Oncol
; 154(1): 83-88, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31029508
17.
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Gynecol Oncol
; 153(3): 535-540, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30979589
18.
Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.
Gynecol Oncol
; 151(3): 449-452, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30266260
19.
Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer.
Oncology
; 90(1): 29-35, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26473609
20.
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 16(5): 561-8, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25882986